A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity (Q33395047)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity |
scientific article |
Statements
1 reference
A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity (English)
1 reference
Ken Hirao
1 reference
Hirofumi Kawamoto
1 reference
Ichiro Sakakihara
1 reference
Yasuhiro Noma
1 reference
Naoki Yamamoto
1 reference
Ryo Harada
1 reference
Koichiro Tsutsumi
1 reference
Masakuni Fujii
1 reference
Hironari Kato
1 reference
Naoko Kurihara
1 reference
Osamu Mizuno
1 reference
Tsuneyoshi Ogawa
1 reference
Etsuji Ishida
1 reference
Kazuhide Yamamoto
1 reference
26 April 2011
1 reference
1 reference
16
1 reference
637-645
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference